Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2261-2266

  Schmitz, S ^a   Hamoir, M ^a   Reychler, H ^a   Magremanne, M ^a   Weynand, B ^a   Lhommel, R ^a   Hanin, F X ^a   Duprez, T ^a   Michoux, N ^a   Rommel, D ^a   Lonneux, M ^a   Cappoen, N ^a   Gillain, A ^a   Machiels, J P ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Cetuximab; Head and neck cancer; Targeted therapy

Indexed keywords

CETUXIMAB; KI 67 ANTIGEN;

ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG ACTIVITY; DRUG ERUPTION; DRUG SAFETY; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOCALCEMIA; LOW DRUG DOSE; NAIL; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SHORT COURSE THERAPY; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; TREATMENT RESPONSE; TUMOR BIOPSY;

CETUXIMAB; HEAD AND NECK CANCER; TARGETED THERAPY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84883367731     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt180     Document Type: Article

References (15)

1. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
2. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
3. Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
4. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-151.
5. Pessaux P, Marzano E, Casnedi S et al. Histological outcome after preoperative cetuximab: case-matched control study. Word J Surg 2010; 34: 2765-2772.
6. NeeffHP, Drognitz O, Klock A et al. Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastasis. Int J Colorectal Dis 2012; 27: 635-645.
7. Primdahl H, Nielsen AL, Larsen S et al. Changes from 1992 to 2002 in the pretreatment delay for patients with squamous cell carcinoma of larynx or pharynx: a Danish nationwide survey from DAHANABOUT Acta Oncol 2006; 45: 156-161.
8. Thomas F, Rochaix P, Benlyazid A et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res 2007; 13: 7086-7092.
9. Del Campo JM, Hitt R, Sebastian P et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2011; 105: 618-627.
10. Sunaga N, Oriuchi N, Kaira K et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 2008; 59: 203-210.
11. Di Fabio F, Pinto C, Rojas Llimpe FL et al. The predictive value of 18F-FDG- PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer 2007; 10: 221-227.
12. Vergez S, Delord JP, Thomas F et al. Preclinical and clinical evidence that deoxy- 2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer. Clin Cancer Res 2010; 16: 4434-4445.
13. Mileshkin L, Hicks RJ, Hughes BG et al. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res 2011; 17: 3304-3315.
14. Zander T, Scheffler M, Nogova L et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F] fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 2011; 29: 1701-1708.
15. Vermorken JB, Herbst RS, Leon X et al. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008; 112: 2710-2719.